Ukusinda kweMedi ziinyanga ezili-12.7, ukusinda kwe-immune progression-free survival (iPFS) ziinyanga ezisi-7.2, kwaye izinga lokusinda lonyaka omnye yi-1%. Ngexesha lokuhlalutya, izigulane ze-55 zazisaphila kwaye izigulane ezibini zazikunyango. Izinga lokhuseleko kunye neempendulo ziyafana nohlaziyo lwangaphambili ukusuka kuMeyi ka-12.
I-interleukin-1 receptor accessory protein (IL1RAP) -i-antibody ebophelelayo i-nadunolimab yinkqubo ekhokelayo yaseCantargia kwaye iphandwa kwiimvavanyo ezininzi zeklinikhi ezivavanya iirejimeni zonyango ezidibeneyo kwiintlobo ezahlukeneyo zomhlaza, kunye ne-PDAC eyona nto ifundwa kakhulu. Ukuza kuthi ga ngoku, ngaphezu kwezigulane ze-70 ze-PDAC ziye zafumana unyango kunye ne-nadunolimab ngokudibanisa ne-gemcitabine kunye ne-nab-paclitaxel kwisigaba se-I / IIa sophando lwekliniki lwe-CANFOUR. Uhlaziyo oluxeliweyo namhlanje lusekwe kwiqela lokuqala lezigulane ezingama-33 ezivavanyiweyo ukuba zisebenza kakuhle.
Kuhlalutyo lwexeshana oluhlaziyiweyo, kunye nexesha elide lokulandelelana kunokufundwa kwangaphambili okubangelwa uhlalutyo oluqinileyo, ukusinda okuphakathi kwiinyanga ze-12.7 kunye ne-1-year-survival rate yi-55%. I-Median iPFS ziinyanga ezisi-7.2 kunye ne-iPFS yeenyanga ezi-6 yama-56%. Ngokuthelekisa, idatha yembali kumgca wokuqala wonyango lwezigulane ze-PDAC ezine-gemcitabine kunye ne-nab-paclitaxel zibonisa ukusinda okuphakathi kweenyanga ze-8.5 kunye ne-1-year-survival rate ye-35%, kunye ne-PFS ephakathi kweenyanga ze-5.5 kunye ne-6-inyanga ye-PFS ye-44% 1. Ngexesha lokuhlalutya, izigulane ezimbini zazisafumana unyango kwaye izigulane ze-12 zazisaphila. Okubangela umdla kukuba, izigulane ezi-6 (18%) kulingo ziye zafumana unyango ixesha elingaphezu konyaka omnye.
Iprofayile yokhuseleko ayitshintshanga kuhlaziyo lwangaphambili kunye nezehlo ze-neutropenia kunye ne-febrile neutropenia ziphezulu kunokuba bekulindelwe kwi-chemotherapy kuphela. Ngokucacileyo, i-febrile neutropenia ibonwa kuphela ngexesha lomjikelo wokuqala wonyango kwaye inokuthintelwa kakhulu ngonyango lweprophylactic yi-granulocyte factor factor G-CSF. Kuyathakazelisa ukuba akukho ziganeko ezinzima (ibanga lesi-3 okanye ngaphezulu) i-neuropathy, umphumo oqhelekileyo we-gemcitabine kunye ne-nab-paclitaxel, ziye zabonwa.
Ngaphaya koko, izigulane ezingama-40 ezongezelelweyo zePDAC ziyaphandwa ekwandisweni kolingo lwe-CANFOUR. Iziphumo ezivela kule nxalenye yolu vavanyo zilindeleke ukuba zivuthwe ukuze ziboniswe ngexesha le-H1 2022. I-Cantargia okwangoku ilungiselela ulingo olungenamsebenzi kunye nolunokuba lubalulekileyo kumgca wokuqala womhlaza we-pancreatic. Uyilo kunye namaxesha aya kubhengezwa nje ukuba iingxoxo zamalungiselelo kunye nabaphathi abakhulu bolawulo zigqityiwe.
INTO ONOKUYITHATHA KWELI NQAKU:
- In the updated interim analysis, with a longer follow-up period than previous readouts resulting in a more robust analysis, median survival is 12.
- The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody nadunolimab is Cantargia’s lead program and is investigated in multiple clinical trials evaluating various combination therapy regimens in different forms of cancer, with PDAC being the most extensively studied.
- In comparison, historical data in first line treatment of PDAC patients with gemcitabine and nab-paclitaxel show median survival of 8.
